Previous 10 |
Sun BioPharma ( OTCQB:SNBP ): Q1 GAAP EPS of -$0.31. More news on: Sun BioPharma, Inc., Earnings news and commentary, Tech stocks news, , Read more ...
Enrollment in Second Cohort of PDA Combination Study Completed New Funding Totaling $0.8 Million Secured MINNEAPOLIS, May 14, 2019 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB:SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment ...
Sun BioPharma ( OTCQB:SNBP ): Q4 GAAP EPS of -$0.16. Cash of $1.41M Press Release More news on: Sun BioPharma, Inc., Earnings news and commentary, Tech stocks news, ,
Front-Line Combination Study with Gemcitabine and Nab-Paclitaxel enrolling second Cohort of Phase 1a Company reinstates founder and Executive Chairman, Dr. Michael Cullen as President and Chief Executive Officer, effective November 1, 2018 $2.2M in private financing raised between ...
News, Short Squeeze, Breakout and More Instantly...
Sun BioPharma Inc Company Name:
SNBP Stock Symbol:
OTCMKTS Market:
MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the s...
MINNEAPOLIS, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has announced the change of its corporate name to Panbela Therapeutics, Inc. effective ...
MINNEAPOLIS, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (Nasdaq: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with pancreatic cancer, today provides a business update and reports financial results for the quart...